Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot study in the swine model of lethal cyanide intoxication indicates efficacy of a platinum-methionine complex countermeasure.

Scientific reports·2026
Same author

Flow-mediated endothelial remodeling and inflammation drive developmental vascular susceptibility in ldlr loss of function.

Nature communications·2026
Same author

Optimizing single-lead ECG axis for AI-based detection of myocardial diseases.

NPJ cardiovascular health·2026
Same author

Mitochondrial dysfunction underlies cardiac contractility and growth defects in a zebrafish model of <i>NAA15</i>-related heart disease.

bioRxiv : the preprint server for biology·2026
Same author

Beyond Glycogen Storage: AMPKγ2 Regulates Cardiac Hypertrophy and Electrophysiology via Myosin Interaction.

bioRxiv : the preprint server for biology·2026
Same author

Only Economic Solutions Will Enable the Implementation of Genetic Sequencing in the Real World.

Journal of evaluation in clinical practice·2026
Same journal

Pulmonary Vascular Disease Across the Continuum: From Mechanisms to Precision Care.

Heart failure clinics·2026
Same journal

Long-term Complications of Pulmonary Embolism: Which Is the Optimal Follow-Up?

Heart failure clinics·2026
Same journal

Recent Advances in Pulmonary Hypertension Management.

Heart failure clinics·2026
Same journal

The Role of Machine Learning and Artificial Intelligence in Drug Discovery and Clinical Care of Pulmonary Hypertension.

Heart failure clinics·2026
Same journal

Portopulmonary Hypertension: Current Perspectives.

Heart failure clinics·2026
Same journal

Exercise Training and Cardiac Rehabilitation in Chronic Thromboembolic Pulmonary Hypertension.

Heart failure clinics·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

FISH for Pre-implantation Genetic Diagnosis
07:34

FISH for Pre-implantation Genetic Diagnosis

Published on: February 23, 2011

Clinical screening and genetic testing.

Rahul C Deo1, Calum A MacRae

  • 1Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.

Heart Failure Clinics
|March 30, 2010
PubMed
Summary
This summary is machine-generated.

Genetic disease architecture guides effective clinical screening for cardiomyopathies and inherited diseases. Early, inexpensive, noninvasive tests are key for asymptomatic conditions.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Related Experiment Videos

Last Updated: Jun 14, 2026

FISH for Pre-implantation Genetic Diagnosis
07:34

FISH for Pre-implantation Genetic Diagnosis

Published on: February 23, 2011

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Area of Science:

  • Cardiology
  • Genetics
  • Medical Screening

Background:

  • Clinical screening is most effective for diseases diagnosable early, often before symptoms appear.
  • Genetic factors play a crucial role in the development of many cardiomyopathies and inherited diseases.
  • Understanding disease architecture is essential for developing targeted screening strategies.

Purpose of the Study:

  • To discuss general principles of genetic disease architecture.
  • To guide screening and diagnostic approaches for cardiomyopathies and inherited diseases.
  • To explore how genetic architecture and clinical characteristics influence screening.

Main Methods:

  • Review of genetic disease architecture principles.
  • Analysis of how genetic and clinical factors inform screening strategies.
  • Discussion of diagnostic approaches for inherited cardiac conditions.

Main Results:

  • Genetic architecture provides a framework for understanding disease predisposition and progression.
  • Clinical characteristics of diseases significantly influence the design of screening protocols.
  • The principles discussed can be applied broadly across various inherited cardiomyopathies.

Conclusions:

  • Genetic disease architecture is a fundamental determinant of effective clinical screening.
  • Screening strategies must integrate knowledge of both genetic underpinnings and clinical manifestations.
  • Optimized screening can lead to earlier diagnosis and improved management of inherited cardiac diseases.